Veliparib and talazoparib are 2 additional oral PARP1/PARP2 inhibitors in clinical development that have demonstrated single-agent antitumour activity in both BRCA-positive and BRCA–wild-type tumours.27–29 In this study, E7449 monotherapy demonstrated preliminary antitumour activity in patients with advanced solid tumours, irrespective of BRCA status. This evidence concerns the gene PARP2 and neoplasm.